Stock Track | AnaptysBio Soars in Pre-Market on Upbeat Earnings Outlook

Stock Track11-06

Shares of AnaptysBio Inc (NASDAQ: ANAB) surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled by optimistic analyst expectations and positive sentiment surrounding the company's prospects.

According to an earnings preview, analysts are forecasting AnaptysBio to report a loss of $1.59 per share for the quarter. However, the consensus estimate has risen by nearly 6% over the past three months, indicating growing confidence in the company's performance. Despite the projected loss, Wall Street's median 12-month price target for ANAB stands at $48.50, well above its last closing price of $19.88.

Notably, H.C. Wainwright lowered its price target on AnaptysBio to $52 from $55 but maintained a "Buy" rating on the stock, suggesting the firm remains bullish on the company's long-term outlook. Meanwhile, Leerink Partners also trimmed its target to $45, though this still implies substantial upside potential from current levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101715900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101715900","market":"us","top_or_hot":-1,"title":"Stock Track | AnaptysBio Soars in Pre-Market on Upbeat Earnings Outlook","media":"Stock Track","content":"<p>Shares of AnaptysBio Inc (NASDAQ: ANAB) surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled by optimistic analyst expectations and positive sentiment surrounding the company's prospects.</p>\n\n<p>According to an earnings preview, analysts are forecasting AnaptysBio to report a loss of $1.59 per share for the quarter. However, the consensus estimate has risen by nearly 6% over the past three months, indicating growing confidence in the company's performance. Despite the projected loss, Wall Street's median 12-month price target for ANAB stands at $48.50, well above its last closing price of $19.88.</p>\n\n<p>Notably, H.C. Wainwright lowered its price target on AnaptysBio to $52 from $55 but maintained a \"Buy\" rating on the stock, suggesting the firm remains bullish on the company's long-term outlook. Meanwhile, Leerink Partners also trimmed its target to $45, though this still implies substantial upside potential from current levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AnaptysBio Soars in Pre-Market on Upbeat Earnings Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AnaptysBio Soars in Pre-Market on Upbeat Earnings Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 22:22 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of AnaptysBio Inc (NASDAQ: ANAB) surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANAB","symbol_name":"Anaptysbio Inc","start_time":0,"source_url":"","article_id":"1101715900","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101715900","pubTimestamp":1730902958,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of AnaptysBio Inc  surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled by optimistic analyst expectations and positive sentiment surrounding the company's prospects.According to an earnings preview, analysts are forecasting AnaptysBio to report a loss of $1.59 per share for the quarter. However, the consensus estimate has risen by nearly 6% over the past three months, indicating gro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANAB":"Anaptysbio Inc"},"translate_title":"AnaptysBio因盈利前景乐观而盘前飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":1},"content_text":"Shares of AnaptysBio Inc (NASDAQ: ANAB) surged 5.13% in pre-market trading on Monday, as the biotechnology company gained traction ahead of its upcoming quarterly earnings report. The rise was fueled by optimistic analyst expectations and positive sentiment surrounding the company's prospects.\nAccording to an earnings preview, analysts are forecasting AnaptysBio to report a loss of $1.59 per share for the quarter. However, the consensus estimate has risen by nearly 6% over the past three months, indicating growing confidence in the company's performance. Despite the projected loss, Wall Street's median 12-month price target for ANAB stands at $48.50, well above its last closing price of $19.88.\nNotably, H.C. Wainwright lowered its price target on AnaptysBio to $52 from $55 but maintained a \"Buy\" rating on the stock, suggesting the firm remains bullish on the company's long-term outlook. Meanwhile, Leerink Partners also trimmed its target to $45, though this still implies substantial upside potential from current levels.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101715900"}